2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.107 (Poster) Patient Characteristics and Treatment Patterns in Biomarker-Selected Early Non-Small Cell Lung Cancer

PP01.107 (Poster) Patient Characteristics and Treatment Patterns in Biomarker-Selected Early Non-Small Cell Lung Cancer

Pdf Summary

This study analyzed patient characteristics and treatment patterns in early non-small cell lung cancer (eNSCLC) based on specific biomarker mutations. The study found differences in demographic and clinical characteristics between different biomarker subgroups, suggesting the importance of stratifying eNSCLC patients based on these mutations. The most common biomarker mutations in the patient population were ALK, EGFR, KRAS, and wild-type. The majority of patients were treated in the community setting, had commercial insurance, and were White. ALK and EGFR patients were more likely to be non-smokers compared to other populations, and mutations were more commonly found in Asian patients. LDMs were more frequently detected in adenocarcinomas compared to squamous histology, while KRAS mutations were more frequently detected in squamous histology. Approximately half of the patients received no adjuvant treatment, while 37% received adjuvant chemotherapy. Patients with EGFR mutations were more likely to receive targeted therapy. The most common drug combinations used in treatment were cisplatin and pemetrexed, followed by carboplatin and pemetrexed. The findings of this study contribute to improving understanding of patient populations and treatment patterns in patients with specific biomarker mutations, highlighting the importance of personalized treatment approaches based on biomarker status.

Asset Subtitle

Jesse Sussell

Keywords

patient characteristics

treatment patterns

eNSCLC

biomarker mutations

ALK

EGFR

KRAS

adenocarcinomas

squamous histology

targeted therapy